Carnosinemia

Last updated
Carnosinemia
Other namesCarnosinase deficiency [1] or Aminoacyl-histidine dipeptidase deficiency, [2]
Carnosine.svg
Carnosine

Carnosinemia is a rare autosomal recessive [3] metabolic disorder [4] caused by a deficiency of carnosinase, a dipeptidase (a type of enzyme that splits dipeptides into their two amino acid constituents). [5]

Contents

Carnosine is a dipeptide composed of beta-alanine and histidine, and is found in skeletal muscle and cells of the nervous system. [6] This disorder results in an excess of carnosine in the urine, cerebrospinal fluid, blood, and nervous tissue. [7] Neurological disorders associated with a deficiency of carnosinase, and the resulting carnosinemia ("carnosine in the blood") are common. [3] [8] [9]

Symptoms and signs

A variety of neurological symptoms have been associated with carnosinemia. They include: hypotonia, developmental delay, intellectual disability, degeneration of axons, sensory neuropathy, tremors, demyelinization, gray matter anomalies, myoclonic seizures, and loss of purkinje fibers. [3] [4] [8] [9]

Genetics

Carnosinemia has an autosomal recessive pattern of inheritance. Autorecessive.svg
Carnosinemia has an autosomal recessive pattern of inheritance.

The gene for carnosinase is located on chromosome 18, [3] an autosome. The carnosine dipeptidase-1 gene ( CNDP1 ) controls tissue and serum carnosinase. [10] Mutations in CNDP1 are responsible for carnosinase deficiency, resulting in carnosinemia. [3]

Carnosinemia is an autosomal recessive disorder, [3] which means the defective gene is located on an autosome, and two copies of the defective gene - one from each parent - are required to inherit the disorder. The parents of an individual with an autosomal recessive disorder both carry one copy of the defective gene, but usually do not experience any signs or symptoms of the disorder.[ citation needed ]

Diagnosis

Types

Carnosinase in humans has two forms: [11] [12] [13] [14]

1. Cellular, or tissue carnosinase: [12] This form of the enzyme is found in every bodily tissue. It is a dimer, and hydrolyzes both carnosine and anserine, preferring dipeptides that have a histidine monomer in the C-terminus position. [11] [12] Tissue carnosinase is often considered a "nonspecific dipeptidase", [13] [15] based in part on its ability to hydrolyze a range of dipeptide substrates, including those belonging to prolinase. [16]

2. Serum carnosinase: [14] This is the carnosinase found in the blood plasma. Deficiency of this form of carnosinase, along with carnosinuria ("carnosine in the urine"), is the usual metabolic indicator of systemic carnosinase deficiency. [3] [8] [17] Serum carnosinase is a glycoprotein, and splits free carnosine and anserine in the blood. [11] This form of the dipeptidase is not found in human blood until late infancy, slowly rising to adult levels by age 15. [14] Unlike tissue carnosinase, serum carnosinase also hydrolyzes the GABA metabolite homocarnosine. [11] Homocarnosinosis, a neurological disorder resulting in an excess of homocarnosine in the brain, though unaffected by tissue carnosinase, is caused by a deficiency of serum carnosinase in its ability to hydrolyze homocarnosine. [18]

A deficiency of tissue and serum carnosinase, with serum being an indicator, is the underlying metabolic cause of carnosinemia. [7] [9]

Treatment

See also

Related Research Articles

<span class="mw-page-title-main">Occipital horn syndrome</span> Medical condition

Occipital horn syndrome (OHS), formerly considered a variant of Ehlers–Danlos syndrome, is an X-linked recessive mitochondrial and connective tissue disorder. It is caused by a deficiency in the transport of the essential mineral copper, associated with mutations in the ATP7A gene.

<span class="mw-page-title-main">Carnosine</span> Chemical compound

Carnosine (beta-alanyl-L-histidine) is a dipeptide molecule, made up of the amino acids beta-alanine and histidine. It is highly concentrated in muscle and brain tissues. Carnosine was discovered by Russian chemist Vladimir Gulevich.

<span class="mw-page-title-main">Angiotensin-converting enzyme</span> Mammalian protein found in humans

Angiotensin-converting enzyme, or ACE, is a central component of the renin–angiotensin system (RAS), which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin II. Therefore, ACE indirectly increases blood pressure by causing blood vessels to constrict. ACE inhibitors are widely used as pharmaceutical drugs for treatment of cardiovascular diseases.

<span class="mw-page-title-main">6-Pyruvoyltetrahydropterin synthase deficiency</span> Medical condition

6-Pyruvoyltetrahydropterin synthase deficiency is an autosomal recessive disorder that causes malignant hyperphenylalaninemia due to tetrahydrobiopterin deficiency. It is a recessive disorder that is accompanied by hyperphenylalaninemia. Commonly reported symptoms are initial truncal hypotonia, subsequent appendicular hypertonia, bradykinesia, cogwheel rigidity, generalized dystonia, and marked diurnal fluctuation. Other reported clinical features include difficulty in swallowing, oculogyric crises, somnolence, irritability, hyperthermia, and seizures. Chorea, athetosis, hypersalivation, rash with eczema, and sudden death have also been reported. Patients with mild phenotypes may deteriorate if given folate antagonists such as methotrexate, which can interfere with a salvage pathway through which dihydrobiopterin is converted into tetrahydrobiopterin via dihydrofolate reductase. Treatment options include substitution with neurotransmitter precursors, monoamine oxidase inhibitors, and tetrahydrobiopterin. Response to treatment is variable and the long-term and functional outcome is unknown. To provide a basis for improving the understanding of the epidemiology, genotype–phenotype correlation and outcome of these diseases, their impact on the quality of life of patients, and for evaluating diagnostic and therapeutic strategies a patient registry was established by the noncommercial International Working Group on Neurotransmitter Related Disorders (iNTD).

Pyruvate dehydrogenase deficiency is a rare neurodegenerative disorder associated with abnormal mitochondrial metabolism. PDCD is a genetic disease resulting from mutations in one of the components of the pyruvate dehydrogenase complex (PDC). The PDC is a multi-enzyme complex that plays a vital role as a key regulatory step in the central pathways of energy metabolism in the mitochondria. The disorder shows heterogeneous characteristics in both clinical presentation and biochemical abnormality.

<span class="mw-page-title-main">Alpha-1-microglobulin/bikunin precursor</span> Protein-coding gene in the species Homo sapiens

Protein AMBP is a protein that in humans is encoded by the AMBP gene.

<span class="mw-page-title-main">PEPD</span> Protein-coding gene in the species Homo sapiens

Xaa-Pro dipeptidase, also known as prolidase, is an enzyme that in humans is encoded by the PEPD gene. Prolidase is an enzyme in humans that plays a crucial role in protein metabolism and collagen recycling through the catalysis of the rate-limiting step in these chemical reactions. This enzyme is coded by the gene PEPD, located on chromosome 19. Serum prolidase activity is also currently being explored as a biomarker for diseases.

<span class="mw-page-title-main">DPP3</span> Protein-coding gene in the species Homo sapiens

Dipeptidyl-peptidase 3 is an enzyme that in humans is encoded by the DPP3 gene.

<span class="mw-page-title-main">Cathepsin H</span> Protein-coding gene in the species Homo sapiens

Cathepsin H is a protein that in humans is encoded by the CTSH gene.

<span class="mw-page-title-main">ITIH2</span> Protein-coding gene in the species Homo sapiens

Inter-alpha-trypsin inhibitor heavy chain H2 is a protein that in humans is encoded by the ITIH2 gene.

<span class="mw-page-title-main">Dipeptidase 1</span> Protein-coding gene in the species Homo sapiens

Dipeptidase 1 (DPEP1), or renal dipeptidase, is a membrane-bound glycoprotein responsible for hydrolyzing dipeptides. It is found in the microsomal fraction of the porcine kidney cortex. It exists as a disulfide-linked homodimer that is glygosylphosphatidylinositol (GPI)-anchored to the renal brush border of the kidney. The active site on each homodimer is made up of a barrel subunit with binuclear zinc ions that are bridged by the Gly125 side-chain located at the bottom of the barrel.

<span class="mw-page-title-main">GOT1</span> Cytoplasmic enzyme involved in amino acid metabolism

Aspartate aminotransferase, cytoplasmic is an enzyme that in humans is encoded by the GOT1 gene.

<span class="mw-page-title-main">CNDP1</span> Protein-coding gene in the species Homo sapiens

Beta-Ala-His dipeptidase is an enzyme that in humans is encoded by the CNDP1 gene.

<span class="mw-page-title-main">Urocanic aciduria</span> Medical condition

Urocanic aciduria is an autosomal recessive metabolic disorder caused by a deficiency of the enzyme urocanase. It is a secondary disorder of histidine metabolism.

<span class="mw-page-title-main">Acetylcarnosine</span> Chemical compound

N-Acetylcarnosine (NAC) is a naturally occurring compound chemically related to the dipeptide carnosine. The NAC molecular structure is identical to carnosine with the exception that it carries an additional acetyl group. The acetylation makes NAC more resistant to degradation by carnosinase, an enzyme that breaks down carnosine to its constituent amino acids, beta-alanine and histidine.

<span class="mw-page-title-main">Hypertryptophanemia</span> Medical condition

Hypertryptophanemia is a rare autosomal recessive metabolic disorder that results in a massive buildup of the amino acid tryptophan in the blood, with associated symptoms and tryptophanuria.

<span class="mw-page-title-main">X-His dipeptidase</span>

Xaa-His dipeptidase is an enzyme. This enzyme catalyses the following chemical reaction

Xaa-methyl-His dipeptidase is an enzyme. This enzyme catalyses the following chemical reaction

<span class="mw-page-title-main">Cytosol nonspecific dipeptidase</span>

Cytosolic non-specific dipeptidase also known as carnosine dipeptidase 2 is an enzyme that in humans is encoded by the CNDP2 gene. This enzyme catalyses the hydrolysis of dipeptides, preferentially those containing hydrophobic amino acids. The human enzyme uses manganese ions as a cofactor. In addition to its function as a peptidase, the enzyme also functions to generate N-lactoyl amino acids, such as N-lactoyl-phenylalanine, via the process of "reverse proteolysis".

Beta-Ala-His dipeptidase is an enzyme. This enzyme catalyses the following chemical reaction

References

  1. ↑ Online Mendelian Inheritance in Man (OMIM): 212200
  2. ↑ Diseases Database (DDB): 29672
  3. 1 2 3 4 5 6 7 Willi SM, Zhang Y, Hill JB, Phelan MC, Michaelis RC, Holden KR (1997). "A deletion in the long arm of chromosome 18 in a child with serum carnosinase deficiency". Pediatr. Res. 41 (2): 210–213. doi: 10.1203/00006450-199702000-00009 . PMID   9029640.
  4. 1 2 Perry TL, Hansens S, Tischler B, Bunting R, Perry K (1967). "Carnosinemia. A new metabolic disorder associated with neurological disease and mental defect". N. Engl. J. Med. 277 (23): 1219–1227. doi:10.1056/NEJM196712072772302. PMID   6058610.
  5. ↑ Sauerheifer S, Yuan G, Braun GS, Deiner RM, Neumaier M, Gretz N, Floege J, Kriz R, van der Woude F, Moeller MJ (2007). "L-carnosine, a substrate of carnosinase-1, influences glucose metabolism". Diabetes. 56 (10): 2425–2432. doi: 10.2337/db07-0177 . PMID   17601992.
  6. ↑ Rashid I, van Reyk DM, Davies MJ (2007). "Carnosine and its constituents inhibit glycation of low-density lipoproteins that promotes foam cell formation in vitro". FEBS Lett. 581 (5): 1067–1070. doi:10.1016/j.febslet.2007.01.082. PMID   17316626. S2CID   46535145.
  7. 1 2 Gjessing LR, Lunde HA, Morkrid L, Lenney JF, Sjaastad O (1990). "Inborn errors of carnosine and homocarnosine metabolism". J Neural Transm Suppl. 29: 91–106. doi:10.1007/978-3-7091-9050-0_10. ISBN   978-3-211-82142-8. PMID   2358806.
  8. 1 2 3 Terplan KL, Cares HL (1972). "Histopathology of the nervous system in carnosinase enzyme deficiency with mental retardation". Neurology. 22 (6): 644–655. doi:10.1212/wnl.22.6.644. PMID   4673339. S2CID   31717219.
  9. 1 2 3 Wisniewski K, Fleisher L, Rassin D, Lassmann H (1981). "Neurological diseases in a child with carnosinase deficiency". Neuropediatrics. 12 (2): 143–151. doi:10.1055/s-2008-1059647. PMID   7266778.
  10. ↑ Zschocke J, Nebel A, Wicks K, Peters V, El Mokhtari NE, Krawczak M, van der Woude F, Janssen B, Schreiber S (2006). "Allelic variation in the CNDP1 gene and its lack of association with longevity and coronary heart disease". Mech Ageing Dev. 127 (11): 817–820. doi:10.1016/j.mad.2006.08.002. PMID   16965804. S2CID   32393210.
  11. 1 2 3 4 Jackson MC, Kucera CM, Lenney JF (1991). "Purification and properties of human serum carnosinase". Clin Chim Acta. 196 (2–3): 193–205. doi:10.1016/0009-8981(91)90073-L. PMID   1903095.
  12. 1 2 3 Lenney JF, Peppers SC, Kucera-Orallo CM, George RP (1985). "Characterization of human tissue carnosinase". Biochem. J. 228 (3): 653–660. doi:10.1042/bj2280653. PMC   1145034 . PMID   4026801.
  13. 1 2 Lenney JF (1990). "Separation and characterization of two carnosine-splitting cytosolic dipeptides from hog kidney (carnosinase and non-specific dipeptidase)". Biol Chem Hoppe-Seyler. 371 (5): 433–440. doi:10.1515/bchm3.1990.371.1.433. PMID   2378680.
  14. 1 2 3 Lenney JF, George RP, Weiss AM, Kucera CM, Chan PW, Rinz GS (1982). "Human serum carnosinase: characterization, distinction from cellular carnosinase and activation by cadmium". Clin Chim Acta. 123 (3): 221–231. doi:10.1016/0009-8981(82)90166-8. PMID   7116644.
  15. ↑ Peppers SC, Lenney JF (1988). "Bestatin inhibition of human tissue carnosinase, a non-specific cytosolic dipeptidase". Biol Chem Hoppe-Seyler. 369 (12): 1281–1286. doi:10.1515/bchm3.1988.369.2.1281. PMID   3242551.
  16. ↑ Lenney JF (1990). "Human cytosolic carnosinase: evidence of identity with prolinase, a non-specific dipeptidase". Biol Chem Hoppe-Seyler. 371 (2): 167–171. doi:10.1515/bchm3.1990.371.1.167. PMID   2334521.
  17. ↑ van Heeswijk PJ, Trijbels JM, Schretlen ED, van Munster PJ, Monnens LA (1969). "A patient with a deficiency of serum-carnosinase activity". Acta Paediatr. Scand. 58 (6): 584–592. doi:10.1111/j.1651-2227.1969.tb04766.x. PMID   5378348. S2CID   28644179.
  18. ↑ Lenney JF, Peppers SC, Kucera CM, Sjaastad O (1983). "Homocarnosinosis: lack of serum carnosinase is the deficiency probably responsible for elevated brain and CSF homocarnosine". Clin Chim Acta. 132 (2): 157–165. doi:10.1016/0009-8981(83)90243-7. PMID   6616870.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.